Matches in Wikidata for { <http://www.wikidata.org/entity/Q37386059> ?p ?o ?g. }
- Q37386059 description "2007 թվականի ապրիլի 12-ին հրատարակված գիտական հոդված" @default.
- Q37386059 description "article científic" @default.
- Q37386059 description "article scientifique" @default.
- Q37386059 description "articolo scientifico" @default.
- Q37386059 description "artigo científico" @default.
- Q37386059 description "artículu científicu espublizáu en 2007" @default.
- Q37386059 description "bilimsel makale" @default.
- Q37386059 description "scientific article published on 12 April 2007" @default.
- Q37386059 description "vedecký článok" @default.
- Q37386059 description "vetenskaplig artikel" @default.
- Q37386059 description "videnskabelig artikel" @default.
- Q37386059 description "vědecký článek" @default.
- Q37386059 description "wetenschappelijk artikel" @default.
- Q37386059 description "wissenschaftlicher Artikel" @default.
- Q37386059 description "наукова стаття, опублікована у квітні 2007" @default.
- Q37386059 description "научни чланак" @default.
- Q37386059 description "مقالة علمية نشرت في 12 أبريل 2007" @default.
- Q37386059 name "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 name "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 name "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 type Item @default.
- Q37386059 label "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 label "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 label "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 prefLabel "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 prefLabel "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 prefLabel "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 P1433 Q37386059-31D3D4E7-540D-4D3D-BA33-923F21010B70 @default.
- Q37386059 P1476 Q37386059-FFEB8ED6-67B5-478C-8CF1-7720042AF3B7 @default.
- Q37386059 P2093 Q37386059-1641ECE5-9C55-4BB1-8406-853CE25B74FC @default.
- Q37386059 P2093 Q37386059-338B8E44-811E-46F7-9482-B4060FBA31DA @default.
- Q37386059 P2093 Q37386059-515BB899-3C1A-44A6-806D-BB67316E37BB @default.
- Q37386059 P2093 Q37386059-81ACC33E-57F9-4024-8C62-2BD02AB78DB2 @default.
- Q37386059 P2093 Q37386059-90D6D7A2-5DA3-443C-A9C9-354215DA096B @default.
- Q37386059 P2093 Q37386059-9182FF45-A9E0-4491-A4FA-DC623FA614BD @default.
- Q37386059 P2093 Q37386059-AF7EA302-406A-4722-98CD-1571790EFF1B @default.
- Q37386059 P2093 Q37386059-BAC6CFCF-16C1-4E7B-8555-65712877F27A @default.
- Q37386059 P2093 Q37386059-C8813810-12A5-4C6B-BCAB-EE12E563EA8A @default.
- Q37386059 P2093 Q37386059-FC7C788E-141A-40FC-8879-474AA18A2EB4 @default.
- Q37386059 P2860 Q37386059-0CBCF6B4-73B7-4240-B5C0-DDCC4DF18E5F @default.
- Q37386059 P2860 Q37386059-17DE855B-896E-458F-AB06-28CED63CF7CB @default.
- Q37386059 P2860 Q37386059-1EBD7DF4-8F10-400A-A107-49C148AAFBBD @default.
- Q37386059 P2860 Q37386059-2A0DDF72-E502-4AF5-9692-BFDD7B6670E8 @default.
- Q37386059 P2860 Q37386059-2A30CD39-4C27-42B7-BD26-531B0093D899 @default.
- Q37386059 P2860 Q37386059-31D2834E-5AA4-4767-9C10-7FD7583C930E @default.
- Q37386059 P2860 Q37386059-3296F8EA-1654-4D15-83F7-16430E705D03 @default.
- Q37386059 P2860 Q37386059-3BF8736D-D81E-4022-A4C8-32E82ED66020 @default.
- Q37386059 P2860 Q37386059-45A71779-8168-4323-A50E-03C3F01D8A62 @default.
- Q37386059 P2860 Q37386059-59E4DFE2-26B7-4351-AF2C-B61ABBE98F73 @default.
- Q37386059 P2860 Q37386059-759313BE-5BA5-47B9-867F-516151239922 @default.
- Q37386059 P2860 Q37386059-7BBDD398-6261-4F62-A6D5-83AF0F6CDE0E @default.
- Q37386059 P2860 Q37386059-81D65E7D-2647-47EB-A7D0-B393AC83E0F7 @default.
- Q37386059 P2860 Q37386059-83D29ED0-4F1E-40EA-A6FD-CF71DA43D356 @default.
- Q37386059 P2860 Q37386059-8644C769-1328-4A13-A8DB-047F8C177B42 @default.
- Q37386059 P2860 Q37386059-87ACCBA9-4DD6-450F-A7CD-FCF33D8A89B8 @default.
- Q37386059 P2860 Q37386059-974FF353-6E3B-4184-8113-BBD0E3AB3EA7 @default.
- Q37386059 P2860 Q37386059-97FCC124-EE80-4CB3-881E-1649DCDE9CA8 @default.
- Q37386059 P2860 Q37386059-98B9711E-03D4-4679-8F57-EECD78AC5160 @default.
- Q37386059 P2860 Q37386059-A1BCA8A2-35FF-4E65-97D7-30E1A491C550 @default.
- Q37386059 P2860 Q37386059-B1409B9B-798E-4917-ADA2-B8387002863B @default.
- Q37386059 P2860 Q37386059-B2848AB9-BB7D-44E6-BC34-F27841B8F3AA @default.
- Q37386059 P2860 Q37386059-BFFE98B8-2CA0-4109-B30C-68B873339913 @default.
- Q37386059 P2860 Q37386059-CD0CF678-5B2C-4CC8-95CB-5840CB10B891 @default.
- Q37386059 P2860 Q37386059-D0DA13F3-67D4-4774-95B4-8AA64A8F54DD @default.
- Q37386059 P2860 Q37386059-E299F76B-10A1-4E2E-9A95-1646A98182D7 @default.
- Q37386059 P2860 Q37386059-E79A6177-B068-4C77-9CB7-1FE6660758BF @default.
- Q37386059 P2860 Q37386059-E88BC536-1DE3-463E-9C4D-9AE176B4DA71 @default.
- Q37386059 P2860 Q37386059-ECADEB4B-4073-4E07-A7A9-29DA76F5DD11 @default.
- Q37386059 P2860 Q37386059-F9DFA6C7-84C7-4F63-8850-4729603D6B6C @default.
- Q37386059 P2860 Q37386059-FE467540-DF74-45FD-9BE9-CC84C6CDD79E @default.
- Q37386059 P2888 Q37386059-91295CB5-1CDB-4579-982C-3509C7EED9D0 @default.
- Q37386059 P304 Q37386059-CD18473C-50E1-4EE8-9C05-96ADF8111A19 @default.
- Q37386059 P31 Q37386059-2E5550D7-AE7F-420D-B42A-D8287DDF3B74 @default.
- Q37386059 P356 Q37386059-7D6CE98D-AF8E-4B9C-AADF-47E0F2282F81 @default.
- Q37386059 P433 Q37386059-1848FE6C-819D-49B7-AE10-AD782D71BBE5 @default.
- Q37386059 P478 Q37386059-BBAF8B60-C42D-4C65-9029-13F4BA40DB29 @default.
- Q37386059 P577 Q37386059-A8CEF554-9E41-47BD-88A5-6BE01B7BDCFF @default.
- Q37386059 P698 Q37386059-4058C9CB-D87D-4DDA-9D07-A3CDD808A5FB @default.
- Q37386059 P921 Q37386059-A142472B-C7CE-4550-A6A2-D02257705CF9 @default.
- Q37386059 P921 Q37386059-CE0F088B-1124-4F6E-A654-CD2BF1986697 @default.
- Q37386059 P921 Q37386059-EB72F8E7-ECBE-475A-8953-CF46A6BD6050 @default.
- Q37386059 P932 Q37386059-A4E03FA3-C5FF-4FE2-BD45-B08F3794EADA @default.
- Q37386059 P356 S00280-007-0472-1 @default.
- Q37386059 P698 17429629 @default.
- Q37386059 P1433 Q326137 @default.
- Q37386059 P1476 "Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer" @default.
- Q37386059 P2093 "Ann Marie Ferris" @default.
- Q37386059 P2093 "Anthony F Shields" @default.
- Q37386059 P2093 "Barbara Rusin" @default.
- Q37386059 P2093 "Bassel F El-Rayes" @default.
- Q37386059 P2093 "Lance K Heilbrun" @default.
- Q37386059 P2093 "Mark M Zalupski" @default.
- Q37386059 P2093 "Philip A Philip" @default.
- Q37386059 P2093 "Raghu Venkatramanamoorthy" @default.
- Q37386059 P2093 "Stephanie G Manza" @default.
- Q37386059 P2093 "Ulka Vaishampayan" @default.
- Q37386059 P2860 Q24336248 @default.
- Q37386059 P2860 Q27860904 @default.
- Q37386059 P2860 Q28036747 @default.
- Q37386059 P2860 Q28189472 @default.